Trial Profile
The effects of AT1 receptor blocker (telmisartan) on serum lipid with hypertensive patients associated with multiple risk factors for cardiovascular disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2012
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Calcium channel antagonists
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- 16 Apr 2012 New trial record